|Assessment Status||Assessment Process Complete|
|Indication||As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy.|
|Rapid review commissioned||25/01/2021|
|Rapid review completed||03/03/2021|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||24/03/2021|
|Pre-submission consultation with Applicant||20/04/2021|
|Full submission received from Applicant||10/06/2021|
|Preliminary review sent to Applicant||28/09/2021|
|NCPE assessment re-commenced||22/10/2021|
|Factual accuracy sent to applicant||29/11/2021|
|NCPE assessment re-commenced||06/12/2021|
|NCPE assessment completed||22/12/2021|
|NCPE assessment outcome||The NCPE recommends that avelumab (Bavencio®), for first-line maintenance treatment of adult patients with bladder cancer who are disease free following platinum-based chemotherapy, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations September 2022.